1 |
<p align="center"><b>RESEARCH AND DEVELOPMENT</b></p> |
2 |
<p>PLIVA has a long and successful R&D track record that dates back to 1936. Its |
3 |
investments in R&D have grown to a decade high of USD 40 m and represent 10% |
4 |
of PLIVA's healthcare turnover. The strategic goal for this continued investment |
5 |
is to achieve a balanced portfolio for PLIVA's short, medium and long-term growth. |
6 |
Commitment to a unique two-fold R&D strategy: the discovery and development of new |
7 |
chemical entities and the development of value added generics, is further supported |
8 |
by PLIVA's licensing strategy.</p> |
9 |
<p>PLIVA has focused its expertise on NCE research, and through this "Smart Discovery Strategy" globally |
10 |
competitive results are expected. Research activities are focusing on the early |
11 |
phases of discovery and development only (i.e. Phase I/II clinical trials), |
12 |
while for advanced stages of development |
13 |
and marketing, strategic partnerships will be established. PLIVA's vision in |
14 |
research is to develop new drugs whose production will serve unmet medical needs |
15 |
and will have commercial returns in line with PLIVA's growth targets.</p> |
16 |
<p align="center"><img src="p/Superrnd_ljudi_4.jpg" width="300" height="198" border=1></p> |
17 |
<p>In development, superior results will be achieved by the in-house development |
18 |
of new molecules, the development of final pharmaceutical Rx or OTC drug forms |
19 |
and the development of Fine Chemicals processes. PLIVA's Competitive Generic |
20 |
Strategy is based on decades of experience and expertise in new API development |
21 |
coupled with regular and successful FDA inspections as well as PLIVA's excellence |
22 |
in chemistry and the innovative improvement of existing drugs.</p> |
23 |
<p>Our R&D strategy binds together a top quality international research team, |
24 |
a network of strategic partnerships with multinational and biotech companies |
25 |
and a broad cooperation with various international universities and institutes. |
26 |
These activities are further supported by an independent body that consists |
27 |
of leading experts in the R&D areas of interest to PLIVA - PLIVA's International |
28 |
Scientific Advisory Board.</p> |